Mucosal antibody responses to vaccines targeting SIV protease cleavage sites or full-length Gag and Env proteins in Mauritian cynomolgus macaques

PloS One
Hongzhao LiMa Luo

Abstract

HIV mutates rapidly and infects CD4+ T cells, especially when they are activated. A vaccine targeting conserved, essential viral elements while limiting CD4+ T cell activation could be effective. Learning from natural immunity observed in a group of highly HIV-1 exposed seronegative Kenyan female sex workers, we are testing a novel candidate HIV vaccine targeting the 12 viral protease cleavage sites (PCSs) (the PCS vaccine), in comparison with a vaccine targeting full-length Gag and Env (the Gag/Env vaccine) in a Mauritian cynomolgus macaque/SIV model. In this study we evaluated these vaccines for induction of mucosal antibodies to SIV immunogens at the female genital tract. Bio-Plex and Western blot analyses of cervicovaginal lavage samples showed that both the PCS and Gag/Env vaccines can elicit mucosal IgG antibody responses to SIV immunogens. Significantly higher increase of anti-PCS antibodies was induced by the PCS vaccine than by the Gag/Env vaccine (p<0.0001). The effect of the mucosal antibody responses in protection from repeated low dose pathogenic SIVmac251 challenges is being evaluated.

References

Jun 1, 1996·Journal of Virology·S LuH L Robinson
Apr 2, 1998·Pharmaceutical Research·M TobíoM J Alonso
Jul 29, 1998·Journal of Molecular Biology·L CraigJ K Scott
Mar 7, 2003·Lancet·Michael McCarthy
Jan 20, 2004·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Ana VilaMaría José Alonso
Aug 6, 2004·Journal of Aerosol Medicine : the Official Journal of the International Society for Aerosols in Medicine·A VilaM J Alonso
Dec 14, 2004·Journal of Controlled Release : Official Journal of the Controlled Release Society·C PregoM J Alonso
Jul 14, 2006·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Marie NguyenGianfranco Pancino
Dec 23, 2006·Retrovirology·James B Whitney, Mark A Wainberg
Dec 7, 2007·PLoS Pathogens·Morgane RollandJames I Mullins
Jun 19, 2009·Expert Opinion on Therapeutic Targets·Catherine S AdamsonEric O Freed
Aug 12, 2009·The Journal of Biological Chemistry·Barbara MüllerHans-Georg Kräusslich
Oct 22, 2009·The New England Journal of Medicine·Supachai Rerks-NgarmUNKNOWN MOPH-TAVEG Investigators
May 1, 2010·Human Vaccines·Stanley A Plotkin
Jul 16, 2010·Nature·Cassandra Willyard
Sep 9, 2010·Expert Review of Vaccines·Monica VaccariGenoveffa Franchini
Nov 9, 2010·Current HIV Research·Shan LuShixia Wang
Nov 17, 2011·Vaccine·Vincent PavotStéphane Paul
Jan 24, 2012·Current HIV Research·Denis M TebitMiguel E Quiñones-Mateu
May 9, 2012·International Journal of Pharmaceutics·J F Correia-PintoM J Alonso
Apr 25, 2013·PloS One·Sara VicenteMaria J Alonso
May 13, 2014·Scandinavian Journal of Immunology·D LemaJ B De Sanctis
Jul 11, 2014·AIDS·Vincent PavotStéphane Paul

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR
transfection
lavage

Software Mentioned

GraphPad Prism

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.